BRAIN Biotech Group announce 3M FY 24/25
Starting the year with double digit sales growth in the core BRAINBiocatalysts division
- BRAINBiocatalysts organic growth at 11 % in Q1
- Quantitative guidance looking at strong growth and solid adjusted EBITDA margin for BRAINBiocatalysts in FY 2024/25
- Strong cash position maintained at € 17.8 million while reducing financial debt
February 26, 2025, Zwingenberg (Germany) – BRAIN Biotech AG, a leading provider of specialty enzymes and innovative biosolutions for industry has published its financial figures for the first three months of the fiscal year 2024/25. The company is now reporting for the first time on its new two-pillar reporting structure.
BRAIN Biotech Group generated Q1 revenue of € 13.1 million compared to € 12.7 million in the same period of the previous year, representing an increase of 3.0 %. The core division BRAINBiocatalysts demonstrated a strong start to the year by growing sales to € 11.9 million (+11 %).
“We are very pleased to see our main operational division BRAINBiocatalysts grow at 11 % in the first quarter. This marks a strong start to the new financial year and builds a solid base for an optimistic full year outlook.
